Clinical Trial: Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625384) titled 'Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease' on May 19.

Brief Summary: The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease

Study Start Date: May 18

Study Type: INTERVENTIONAL

Condition: Still Disease

Intervention: DRUG: Placebo

0.9% Sodium Chloride solution for Injection

BIOLOGICAL: Goflikicept

solution for subcutaneous injection and intravenous infusion, 40 mg/mL

BIOLOGICAL: Olokizumab

solution for subcutaneous injection and intravenous infusion, 16...